Please login to the form below

Not currently logged in
Email:
Password:

Gyros Protein Technologies appoints chairman

Dr Frank Witney brings experience from Affymetrix and Dionex

Gyros Protein Technologies Dr Frank WitneySwedish Gyros Protein Technologies has appointed Dr Frank Witney as the new chairman of its board, succeeding David Patteson.

Dr Witney brings over 30 years of leadership experience in the life sciences industry, most recently having served as president and chief executive officer of Affymetrix.

He has held a number of executive roles in recent years, including serving as president and chief executive of both Dionex and Panomics, and was Packard Biosciences' chief operating officer before becoming president of life sciences after the firm's acquisition by Perkin Elmer.

Dan Calvo, Gyros Protein Technologies' chief executive, said: “We are delighted that Frank has joined as chairman.

“He brings with him a wealth of experience and knowledge in the field, and his guidance will be invaluable as we work to build Gyros Protein Tehcnologies following the merger earlier this year.”

23rd June 2016

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...

Infographics